Analytical Data
-
Gene name
CBLB
- Application
-
Alternative Names
CBLB; RNF56; Nbla00127; E3 ubiquitin-Protein ligase CBL-B; EC 2.3.2.27; Casitas B-lineage lymphoma proto-oncogene b; RING finger Protein 56; RING-type E3 ubiquitin transferase CBL-B; SH3-binding Protein CBL-B; Signal transduction Protein CBL-B
-
Species
Human
-
Source
E. coli
-
Tag
GST-tag at N-terminal
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q13191
-
Expression Region
1-982aa
-
AA Sequence
MANSMNGRNPGGRGGNPRKGRILGIIDAIQDAVGPPKQAAADRRTVEKTWKLMDKVVRLCQNPKLQLKNSPPYILDILPDTYQHLRLILSKYDDNQKLAQLSENEYFKIYIDSLMKKSKRAIRLFKEGKERMYEEQSQDRRNLTKLSLIFSHMLAEIKAIFPNGQFQGDNFRITKADAAEFWRKFFGDKTIVPWKVFRQCLHEVHQISSGLEAMALKSTIDLTCNDYISVFEFDIFTRLFQPWGSILRNWNFLAVTHPGYMAFLTYDEVKARLQKYSTKPGSYIFRLSCTRLGQWAIGYVTGDGNILQTIPHNKPLFQALIDGSREGFYLYPDGRSYNPDLTGLCEPTPHDHIKVTQEQYELYCEMGSTFQLCKICAENDKDVKIEPCGHLMCTSCLTAWQESDGQGCPFCRCEIKGTEPIIVDPFDPRDEGSRCCSIIDPFGMPMLDLDDDDDREESLMMNRLANVRKCTDRQNSPVTSPGSSPLAQRRKPQPDPLQIPHLSLPPVPPRLDLIQKGIVRSPCGSPTGSPKSSPCMVRKQDKPLPAPPPPLRDPPPPPPERPPPIPPDNRLSRHIHHVESVPSKDPPMPLEAWCPRDVFGTNQLVGCRLLGEGSPKPGITASSNVNGRHSRVGSDPVLMRKHRRHDLPLEGAKVFSNGHLGSEEYDVPPRLSPPPPVTTLLPSIKCTGPLANSLSEKTRDPVEEDDDEYKIPSSHPVSLNSQPSHCHNVKPPVRSCDNGHCMLNGTHGPSSEKKSNIPDLSIYLKGDVFDSASDPVPLPPARPPTRDNPKHGSSLNRTPSDYDLLIPPLGEDAFDALPPSLPPPPPPARHSLIEHSKPPGSSSRPSSGQDLFLLPSDPFVDLASGQVPLPPARRLPGENVKTNRTSQDYDQLPSCSDGSQAPARPPKPRPRRTAPEIHHRKPHGPEAALENVDAKIAKLMGEGYAFEEVKRALEIAQNNVEVARSILREFAFPPPVSPRLNL
-
Molecular Weight
135.8 KDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of CBLB (Cbl-b) recombinant proteins has gained significant attention in the field of immunology and cancer research. Cbl-b is an E3 ubiquitin ligase that plays a crucial role in the negative regulation of T cell activation and proliferation. Its function is essential for maintaining immune homeostasis and preventing autoimmune diseases. In the context of cancer, Cbl-b has emerged as a potential target for immunotherapeutic strategies since its activity can influence the immune system's ability to recognize and eliminate tumor cells. Researchers have been increasingly focused on understanding the molecular mechanisms underlying Cbl-b's role in modulating T cell responses and exploring its potential as a biomarker for cancer prognosis and treatment response. The development of recombinant CBLB proteins allows for detailed studies on its interaction with various cellular signaling pathways and provides a framework for designing targeted therapies that could enhance anti-tumor immunity. Additionally, the ability to produce CBLB proteins in a recombinant form facilitates high-throughput screening approaches to identify novel compounds that can modulate Cbl-b activity, paving the way for innovative immunomodulatory therapies. Overall, the research surrounding CBLB recombinant proteins is pivotal in advancing our knowledge of immune regulation and developing effective strategies for enhancing anti-cancer immunity.
